Oxycodone Depot Orion

Active Ingredient:: Oxycodone Hydrochloride
Origin:: EU

Oxycodone Depot Orion (Oxycodone Hydrochloride)

International sale not permitted. Listed for the domestic market and B2B only.

Oxycodone Hydrochloride, the active ingredient in Oxycodone Depot Orion, is a opioid analgesic presented as a depot formulation for oral use. It is intended for the management of moderate to severe chronic pain in adult patients who require continuous, long‑acting opioid therapy.

GNH India supplies Oxycodone Depot Orion as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

Manufacturer / TM Owner

Orion Corporation

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Oxycodone Depot Orion is an opioid analgesic that acts on the central nervous system to relieve pain.

Chronic cancer‑related pain: provides sustained relief over several days, reducing the need for multiple daily doses.
Severe non‑cancer chronic pain: maintains steady plasma concentrations for continuous analgesia.
Post‑operative pain requiring extended control: offers prolonged pain control when oral dosing is impractical.

How It Works

Oxycodone Hydrochloride binds to μ‑opioid receptors in the central nervous system, activating inhibitory G‑protein pathways that decrease neuronal excitability and reduce the perception of pain. The depot formulation releases the drug slowly, maintaining therapeutic plasma levels over an extended period.

Side Effects

Adverse reactions to Oxycodone Depot Orion vary in frequency and severity.

Common Side Effects

Nausea: mild to moderate upset stomach.
Constipation: reduced bowel motility.
Drowsiness: increased sleepiness or fatigue.
Dry mouth: reduced salivary flow.
Dizziness: light‑headed sensation.
Itching: mild skin pruritus.

Serious or Rare Side Effects

Respiratory depression: slowed or shallow breathing.
Severe hypotension: marked drop in blood pressure.
Opioid dependence or addiction: potential for misuse.
Seizures: rare convulsive episodes.
Anaphylaxis: acute allergic reaction with airway compromise.

Precautions & Warnings

When prescribing Oxycodone Depot Orion, clinicians should consider several safety measures.

Assess pain severity and opioid tolerance: ensure the patient requires long‑acting opioid therapy.
Review medical history: identify respiratory disorders, head injury, or gastrointestinal obstruction.
Monitor for signs of dependence: watch for cravings or uncontrolled use.
Avoid concurrent CNS depressants: limit use with alcohol, benzodiazepines, or other sedatives.
Educate patients on proper use: stress the importance of adhering to prescribed intervals.
Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Avoid Interactions

Oxycodone Depot Orion can interact with several medication classes, requiring careful management.

Major Interactions (Avoid)

Benzodiazepines: combined use can cause profound respiratory depression.
Central nervous system depressants: alcohol or barbiturates may intensify sedation and respiratory effects.
MAO inhibitors: concurrent use can precipitate hypertensive crisis.

Moderate Interactions (Monitor Closely)

CYP3A4 inhibitors (e.g., ketoconazole): may increase oxy‑related plasma levels.
CYP3A4 inducers (e.g., rifampicin): may reduce analgesic effectiveness.
Anticholinergic agents: can worsen constipation and urinary retention.

Frequently Asked Questions

Oxycodone Depot Orion is a long‑acting opioid formulation designed to provide continuous pain relief for adults with moderate to severe chronic pain, such as cancer‑related pain or persistent non‑cancer pain, when around‑the‑clock analgesia is required.

The oxycodone component binds to μ‑opioid receptors in the brain and spinal cord, activating inhibitory pathways that lower neuronal firing and diminish the perception of pain. The depot matrix releases the drug slowly, keeping plasma concentrations stable over several days.

Dosing is individualized; the prescribing clinician determines the appropriate strength and dosing interval based on the patient’s pain intensity, prior opioid exposure, and overall health status. No fixed regimen is provided here.

Opioids cross the placenta and are excreted in breast milk, potentially causing respiratory depression in the newborn. Use is generally contraindicated unless the benefit to the mother clearly outweighs the risk to the fetus or infant, and it should be prescribed only under specialist supervision.

Submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any required import documentation.

Compared with immediate‑release oxycodone tablets, the depot formulation offers a prolonged duration of action, reducing dosing frequency and improving adherence. It differs from transdermal fentanyl by providing oral administration and a distinct safety profile, while still delivering strong analgesia.

Store the product at ambient temperature, below 25 °C, in its original packaging. Protect it from moisture, direct sunlight and excessive heat to maintain potency and prevent degradation.

The medication is taken orally as a single tablet or capsule, depending on the specific product format, and is intended for once‑every‑few‑days dosing as directed by the prescribing clinician.

The most critical concerns include respiratory depression, severe hypotension, opioid dependence or addiction, and rare but life‑threatening allergic reactions such as anaphylaxis. Patients should be monitored closely, especially during initiation and dose adjustments.

Individuals with known hypersensitivity to oxycodone or any formulation component, those with severe respiratory insufficiency, acute or severe asthma, paralytic ileus, or untreated severe head injury should avoid this medication. It is also contraindicated in patients taking monoamine oxidase inhibitors.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 10 Oct 2026

Disclaimer

International sale not permitted. Listed for the domestic market and B2B only.

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.